Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology (FOCUSO)

Neolys

Status: Enrolling

Conditions: Radiation Toxicity; Radiosensitivity; Pediatric Cancer

Treatments: Biological: Blood sample

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT06033183

FOCUSO

Details and patient eligibility

About

Analysis of the individual radiosensitivity in pediatric oncology

Enrollment: 100 estimated patients

Sex: All

Ages: 3 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes.
• Children or adolescents > 3 years old and < 18 years old
• Patient with an indication for radiotherapy as part of the primary tumor local control strategy
• Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used
• Patient affiliated with a social security scheme
• Patient and/or parents or holders of parental authority having dated and signed an informed consent

Exclusion criteria

• Patients with contraindications to blood sampling
• Patients with contraindications to radiotherapy
• Palliative radiotherapy
• Patient with previous RT treatment in the same area (re-irradiation)
• Patient with an indication of hypofractionated RT
• Patient follow-up not possible
• Persons deprived of liberty or under guardianship (including curatorship)

Exclusion Criteria:

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Radiosensitivity

Experimental group

Description:

Patients who agree to participate in this research study will have blood sample collected to perform the RadioDtect test

Treatment:

Biological: Blood sample